HUTCHMED

13
23.0800.86% ( -0.200 )
Delay Closed: Nov 16, 16:08:11

Overview

HUTCHMED (13)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and...

Open
23.260
High
23.280
Low
22.800
Prev. Close
23.280
Volume
2.62M
Turnover
60.43M
Avg Price
23.049
Bid/Ask Ratio
20.00%
Amplitude
2.06%
52wk High
25.580
Volume Ratio
0.63
Turnover Ratio
0.30%
52wk Low
15.570
HK Mkt Cap
20.13B
Market CapHKD
20.13B
P/ETTM
143.57
P/EDynamic
80.60
P/EStatic
--
EPSTTM
0.161
EPSDynamic
0.286
EPSStatic
--
BVPS
11.33
P/B
2.04
HK Shares
872.34M
Dividend YieldTTM
--
DividendTTM
--
Shares
872.34M
Min lot size
500
Currency
HKD

HUTCHMED Analyst Rating

View more

Forecast & Rating

Nov 5, 2026
Price forecast
HK$32.9042.54%
Forecast & RatingStrong buy
17analysts
  • Strong buy82.35%
  • Buy11.76%
  • Hold5.88%
  • Sell0.00%
  • Strong sell0.00%

News

Bullish vs. Bearish — Last 3 Months

2.9k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • F
    FaithAnchor

    $JMSEA(C07.SG)

    Jardine C&C’s Strategic Reset: Buy, Hold or Sell?

    Jardine Cycle & Carriage is selling its Singapore and Malaysia Cycle & Carriage operations to Chandra Asri for about S$265m, with a potential S$30m earn-out. The bigger story is portfolio discipline: management is exiting a mature, capital-intensive legacy business and concentrating on higher-growth Indonesia and Vietnam.

    The deal looks financially attractive. The assets generated only US$16m of 1H26 profit, against an estimated US$221m disposal gain. Importantly, proceeds will be used to reduce corporate debt. Corporate net debt had already fallen from US$577m to US$286m by June 2026.

    For shareholders, the transaction lifts pro-forma NTA 2.4% and reported EPS 20.8%, although underlying EPS falls 3.9% because the sold business is removed.

    At around S$27.06, C07 trades near 8.4x earnings, with a ~5.2% dividend yield. Technically, it remains weak, sitting close to its 52-week low of S$26.01, while the consensus target is only S$28.25.

    Verdict: HOLD. The strategic reset is positive, but much is already reflected. The ~US¢73 special dividend is linked to the Toyota divestment, not the Cycle & Carriage sale.

    Not financial advice.

    C07 LEVELS UP! Jardine Cycle & Carriage JARDINE C&C DIVESTS LEGACY MOTOR BUSINES
    Trade Showcase: Trade, Show & Earn Rewards!